Skip to content

Author

Irfan Bugday

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Comparative Evaluation of the Effectiveness of Nivolumab Versus Axitinib in the Second-Line Treatment of Patients with Metastatic Renal Cell Carcinoma: A Two-Center Experience

In this two-center retrospective cohort, nivolumab was associated with longer PFS and OS than axitinib in the second-line treatment of mRCC, and these associations remained significant after adjustment for IMDC risk group and year of treatment initiation.

Irfan Bugday, İlknur Deliktaş Onur, M. Inanc et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.